{"Symbol": "ANL", "AssetType": "Common Stock", "Name": "Adlai Nortye Ltd. American Depositary Shares", "Description": "Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. The company is headquartered in Grand Cayman, the Cayman Islands.", "CIK": "1944552", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS, KY1-1104", "OfficialSite": "https://www.adlainortye.com", "FiscalYearEnd": "December", "LatestQuarter": "2024-06-30", "MarketCapitalization": "350922000", "EBITDA": "-41885000", "PERatio": "None", "PEGRatio": "None", "BookValue": "0.215", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-1.14", "RevenuePerShareTTM": "0.061", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.298", "ReturnOnEquityTTM": "-1.39", "RevenueTTM": "1940000", "GrossProfitTTM": "1940000", "DilutedEPSTTM": "-1.14", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "1.18", "AnalystTargetPrice": "31", "AnalystRatingStrongBuy": "0", "AnalystRatingBuy": "1", "AnalystRatingHold": "1", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "15.5", "PriceToBookRatio": "44.3", "EVToRevenue": "3.806", "EVToEBITDA": "-", "Beta": "-1.878", "52WeekHigh": "12.09", "52WeekLow": "0.879", "50DayMovingAverage": "3.565", "200DayMovingAverage": "2.122", "SharesOutstanding": "31236900", "SharesFloat": "57077000", "PercentInsiders": "8.590", "PercentInstitutions": "0.215", "DividendDate": "None", "ExDividendDate": "None"}